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Abstract The chemical similarity between some synthetic
agonists of vanilloid receptors, such as olvanil (N-vanillyl-cis-9-
octadecenoamide), and the ‘endocannabinoid’ anandamide (ara-
chidonoyl-ethanolamide, AEA), suggests possible interactions
between the cannabinoid and vanilloid signalling systems. Here
we report that olvanil is a stable and potent inhibitor of AEA
facilitated transport into rat basophilic leukemia (RBL-2H3)
cells. Olvanil blocked both the uptake and the hydrolysis of
[14C]AEA by intact RBL-2H3 cells (IC50 = 9 WM), while
capsaicin and pseudocapsaicin (N-vanillyl-nonanamide) were
much less active. Olvanil was more potent than previously
reported inhibitors of AEA facilitated transport, i.e. phloretin
(IC50 = 80 WM), AM404 (12.9% inhibition at 10 WM) or
oleoylethanolamide (27.5% inhibition at 10 WM). Olvanil was a
poor inhibitor of [14C]AEA hydrolysis by RBL-2H3 and
N18TG2 cell membranes, suggesting that the inhibitory effect
on [14C]AEA breakdown observed in intact cells was due to
inhibition of [14C]AEA uptake. Olvanil was stable to enzymatic
hydrolysis, and (i) displaced the binding of high affinity
cannabinoid receptor ligands to membrane preparations from
N18TG2 cells and guinea pig forebrain (Ki = 1.64^7.08 WM), but
not from cells expressing the CB2 cannabinoid receptor subtype;
(ii) inhibited forskolin-induced cAMP formation in intact
N18TG2 cells (IC50 = 1.60 WM), this effect being reversed by
the selective CB1 antagonist SR141716A. Pseudocapsaicin, but
not capsaicin, also selectively bound to CB1 receptor-containing
membranes. These data suggest that some of the analgesic
actions of olvanil may be due to its interactions with the
endogenous cannabinoid system, and may lead to the design of a
novel class of cannabimimetics with potential therapeutic
applications as analgesics.
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1. Introduction
Evidence exists for the presence, in sensory neurons and
some peripheral tissues, of distinct types of vanilloid receptors
that are activated by the natural component of chili peppers,
capsaicin (N-(3-methoxy-4-hydroxy-benzyl)-8-methyl-6-trans-
nonenamide or N-vanillyl-8-methyl-6-trans-nonenamide, Fig.
1), and antagonized by capsazepine (for a review [1]). One
of these receptors was recently cloned and shown to mediate
capsaicin e¡ects in dorsal root ganglia [2]. The presence of at
least one additional vanilloid receptor is suggested by studies
carried out with resiniferatoxin, a phorbol derivative, the pat-
tern of whose pharmacological actions di¡ers from that of
capsaicin [3]. A synthetic vanilloid derivative and anti-in£am-
matory/analgesic compound, N-(3-methoxy-4-hydroxy-ben-
zyl)-cis-9-octadecenoamide (olvanil, [4,5], Fig. 1), was also
suggested to bind to a special subtype of vanilloid receptors
based on its non-pungency, lower toxicity and slower activa-
tion kinetics of Ca2 inward currents as compared to capsai-
cin [5,6]. It is not known whether olvanil binds to the recently
cloned VR1 vanilloid receptor [2].
The pharmacology and biochemistry of cannabinoid recep-
tors are better known than those of vanilloid receptors (for a
recent review see [7]). Two di¡erent receptor subtypes, named
CB1 and CB2, have been identi¢ed and cloned from mamma-
lian tissues [7], and endogenous ligands for these proteins have
been found. The best known ‘endocannabinoid’ is anand-
amide (arachidonoylethanolamide, AEA, [8]), whose human
and rat tissue distribution, biosynthetic and catabolic path-
ways, and pharmacological actions have been thoroughly
studied (recently reviewed in [9]). It has been proposed that
the action of AEA is terminated by facilitated transport into
cells followed by enzymatic hydrolysis of the amide bond.
Evidence for a membrane ‘carrier’ protein selective for AEA
has been provided for rat central neurons [10,11] and rat
cerebellar granule cells [12] ^ which selectively express CB1
receptors [7] ^ and rat basophilic leukemia (RBL-2H3) cells
[13] ^ which contain CB2 receptors [7,16]. AEA facilitated
transport is inhibited by alkylating agents [13], phloretin
and oleoylethanolamide [12], and some aromatic derivatives
of AEA such as N-benzyl-arachidonamide [12] and N-(4-hy-
droxyphenyl)-arachidonamide (AM404) [11]. Once inside
cells, AEA is hydrolyzed to arachidonate and ethanolamine
via the action of ‘fatty acid amide hydrolase’ (FAAH), an
enzyme which recognizes as substrates several long chain fatty
acid amides and esters [14,15], including a potent anti-in£am-
matory congener of AEA, palmitoylethanolamide (PEA,
[13,16]).
Starting from the chemical similarity between long chain
capsaicin analogues and AEA or, particularly, aromatic inhib-
itors of AEA facilitated transport [11,12], we have examined
whether capsaicin-like compounds could interact with the best
characterized proteins of the ‘endogenous cannabinoid sys-
tem’, i.e. the AEA ‘carrier’, FAAH and the two cannabinoid
receptor subtypes. We report that olvanil is a potent inhibitor
of AEA facilitated transport into RBL-2H3 cells, and both
olvanil and another capsaicin congener, N-vanillyl-nonan-
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amide (pseudocapsaicin), but not capsaicin, weakly bind to
CB1, but not CB2, cannabinoid receptors.
2. Materials and methods
Mouse neuroblastoma N18TG2, mouse J774 macrophages and
RBL-2H3 cells were cultured as described previously [9,13]. [14C]AEA
and [14C]PEA (5 mCi/mmol) were synthesized as described previously
[8] starting from [14C]ethanolamine and the corresponding fatty acyl
chlorides. Anandamide and oleoylethanolamide were synthesized like-
wise from ethanolamine and arachidonoyl- or oleoyl-chlorides.
[3H]SR 141716A (55 Ci/mmol) was purchased from Amersham,
whereas [3H]CP 55 940 (164 Ci/mmol) and [3H]WIN 55 212-2 (43 Ci/m-
mol) were purchased from NEN. Phloretin, capsaicin and pseudocap-
saicin were purchased from Sigma, forskolin from Fluka, and AM404
from Cayman Chemical. Olvanil was synthesized in the Naples labo-
ratory by reacting 30 mg of 3-methoxy-4-hydroxy-benzylamine with
an excess of oleoylchloride at 4‡C for 30 min. The mixture was then
brought to dryness under a £ow of N2 and puri¢ed by normal phase
high pressure liquid chromatography (NP-HPLC) carried out with a
semi-preparative column (Spherisorb S5W) eluted with a 40-min lin-
ear gradient from 90% to 80% of n-hexane in 2-propanol (£ow rate
2 ml/min). Under these conditions olvanil was eluted after 27 min.
Electron-impact mass spectrometric analysis, carried out on an HP-
5989B quadrupole mass analyzer equipped with an electron impact
source operating at 70 eV and 250‡C, con¢rmed the chemical struc-
ture of the compound (m/z = 417, molecular ion; m/z = 294, loss of a
3-methoxy-4-hydroxy-phenyl group; m/z = 137 and 281, cleavage of
the CH2-NH bond). Experiments with intact cells were carried out
as described previously [13] in six-well dishes (about 1.0U106 cells/
well). Cells were incubated at 37‡C with 0.5 ml of serum-free media
containing 20 000 cpm (4 WM) of either [14C]AEA or [14C]PEA
for 30 min with the substances shown in Figs. 1 and 2. After
having washed the cells three times with 3 ml of 0.2% bovine serum
albumin (BSA)-containing medium, [14C]AEA or [14C]PEA and
[14C]ethanolamine in media and cells were quanti¢ed as described
[13]. Some experiments were also performed in the presence of 50
WM p-hydroxymercuribenzoate. [14C]AEA and [14C]PEA hydrolysis
by cell-free fractions was studied by using 10 000Ug pellets from
RBL-2H3 and N18TG2 cell homogenates prepared as described
[13]. Aliquots of 40^80 Wg total proteins were incubated in 0.5 ml
of 50 mM Tris-HCl, pH 9, with 40 000 cpm of either [14C]AEA or
[14C]PEA for 30 min at 37‡C. [14C]Ethanolamine produced from the
enzymatic hydrolysis was determined as described elsewhere [13]. Ex-
periments on the hydrolysis of olvanil (0.2 mg) by N18TG2 or RBL-
2H3 cell membrane preparations were carried out with 30^300 Wg
total proteins suspended in 0.5 ml Tris-HCl, 50 mM, pH 9.0, and
incubated for 30 min at 37‡C. Aliquots of the membrane preparations
were incubated in parallel with [14C]AEA to con¢rm the presence of
FAAH activity. After the incubation, lipids were extracted and loaded
on analytical thin layer chromatography plates in comparison with
synthetic standards of olvanil and oleic acid. Plates were developed
with chloroform/ methanol/NH3 85:15:1 by vol. and the formation of
oleic acid (Rf = 0.25) monitored by exposing the plate to iodine va-
pors. All the experiments on the e¡ects of olvanil, capsaicin and
pseudocapsaicin on AEA and PEA inactivation were performed in
the Naples laboratory. Binding assays were carried out with guinea-
pig forebrain (GPF) membranes or with membranes from CHO cells
stably transfected with CB2 receptors (CHO-CB2 cells) [18] (in the
Aberdeen laboratory), or with membranes from N18TG2 and RBL-
2H3 cells (in the Naples laboratory). Forebrains from adult male
Dunkin Hartley guinea-pigs were suspended in 50 mM Tris bu¡er
(pH 7.4) and 0.32 M sucrose and homogenized with an Ultra-Turrax
homogenizer. The homogenates were diluted with 50 mM Tris bu¡er
and centrifuged at 100 000Ug for 1 h thus yielding the membranes for
the binding assays. CHO-CB2, N18TG2 and RBL-2H3 cell mem-
branes were prepared as described in [18,19] and [16], respectively.
Binding assays were carried out by using the ¢ltration procedures
described previously [16,18,19] with slight modi¢cations consisting in
the presence of phenylmethylsulfonyl£uoride (PMSF, Sigma, 0.1 mM)
in the respective binding bu¡ers, and the use of di¡erent amounts of
total membrane proteins and radiolabelled ligands ([3H]CP 55 940 for
GPF and CHO-CB2 membranes, [3H]SR 141716A for N18TG2 mem-
branes, and [3H]WIN 55 212-2 for RBL-2H3 membranes). Speci¢c
binding was calculated by using either 1 WM unlabelled CP 55 940,
or 10 WM unlabelled SR 141716A (kindly donated by Sano¢ Re-
cherche, Montpellier) or HU-210 (kindly donated by Prof. R. Me-
choulam, The Hebrew University of Jerusalem). The concentration
of unlabelled ligand that produced a 50% displacement of the labelled
ligands from speci¢c binding sites was calculated using GraphPad
Prism (GraphPad Software, San Diego, CA, USA). Ki values were
calculated by means of the Cheng-Pruso¡ equation from the Kd val-
ues for each radiolabelled ligand in each of the membrane systems
used. Cyclic AMP (cAMP) assays were performed in the Naples lab-
oratory on intact con£uent N18TG2 cells plated in six-well dishes and
stimulated for 10 min at 37‡C with 1 WM forskolin in 400 Wl of serum-
free Dulbecco’s modi¢ed Eagle’s Medium containing 20 mM HEPES,
0.1 mg/ml BSA, 0.1 mM 1-methyl-3-isobutylxanthine (Sigma) and
either vehicle (ethanol) or anandamide, olvanil and olvanil plus SR
141716A at the concentrations shown in Fig. 3. After the incubation
cells were extracted, and cAMP levels determined by means of a
cAMP assay kit (Amersham), as advised by the manufacturer.
3. Results and discussion
In a previous study [13] we showed that, in RBL-2H3 cells,
distinct uptake mechanisms exist for AEA and its anti-in£am-
matory congener PEA [16]. The di¡usion of both acylethanol-
amides into intact RBL-2H3 cells was maximal after 20^30-
min incubations, saturable, inhibited by N-ethylmaleimide
and PMSF, and greatly reduced at 0^4‡C. However, the two
compounds did not compete for each other’s uptake. RBL-
2H3 cells were also found to express an ‘AEA amidohydro-
lase’ activity [13] which was later identi¢ed as FAAH [17]. In
agreement with the presence of distinct transporter proteins
for the two acylethanolamides in RBL-2H3 cells, here we
found that olvanil inhibits the facilitated di¡usion of
[14C]AEA, but not [14C]PEA, thereby signi¢cantly increasing
the amount of extracellular AEA potentially available for
cannabinoid receptor activation (Fig. 2A and data not
shown). The inhibitory e¡ect of olvanil (estimated
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Fig. 1. Chemical structures of capsaicin, pseudocapsaicin and
olvanil.
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IC50 = 9 þ 2 WM, n = 3) on [14C]AEA di¡used into cells after
30-min incubations at 37‡C was more potent than that ob-
served here with previously described [11,12] blockers of AEA
facilitated di¡usion such as phloretin (estimated IC50 =
80 WM), oleoylethanolamide (27.5% inhibition at 10 WM) or
AM404 (12.9% inhibition at 10 WM) (Fig. 2B). The data ob-
tained with the former two compounds are in good agreement
with those previously reported for the inhibition of AEA dif-
fusion into rat cerebellar granule cells [12], also in view of the
fact that the concentration of radiolabelled AEA used in the
previous study (0.3 nM) was much lower than that used here
(4 WM). The high concentration of the radiolabelled ligand
used in the present study may indeed explain why AM404
was much less e¡ective against [14C]AEA uptake by RBL-
2H3 cells than previously described for cortical astrocytes
and neurons (IC50 = 1^5 WM, [11]). We thought that this could
have been due also to the longer incubation time used here as
compared to the previous study [11], and, therefore, per-
formed experiments looking at the e¡ect of inhibitors on
[14C]AEA di¡used into cells after 15-min incubations. This
resulted in a slightly increased potency for oleoylethanolamide
(32.1% inhibition at 10 WM) but not AM404 (14.5% inhibition
at 10 WM) (data not shown). With 30-min incubations, olvanil
also inhibited [14C]AEA hydrolysis by intact RBL-2H3 cells
with an estimated IC50 of 9 WM (Fig. 2A). Since the vanilloid
compound inhibited [14C]AEA hydrolysis by RBL-2H3 mem-
brane preparations at higher concentrations (IC50 = 32 þ 1 WM,
n = 3, Fig. 2C), it is possible that the inhibitory e¡ect observed
in intact cells was due to inhibition of AEA facilitated di¡u-
sion, which precedes enzymatic hydrolysis (as shown in [10],
the t1=2 values for AEA uptake and hydrolysis by rat cortical
neurons are 2.5 and 6 min, respectively; moreover, the sub-
cellular distribution of FAAH, described in [29], seems to rule
out that anandamide is hydrolyzed by intact cells prior to its
internalization). Olvanil also inhibited [14C]AEA hydrolysis by
N18TG2 membrane preparations ^ where FAAH expression
has been shown [17] ^ but again only at high concentrations
(IC50 = 48 þ 2 WM). However, in order to isolate the e¡ect of
olvanil on the AEA carrier from its weak e¡ect on FAAH, we
studied the uptake of [14C]AEA by RBL-2H3 cells in the
presence of p-hydroxymercuribenzoate at a concentration
(50 WM) found to counteract [14C]AEA hydrolysis without
greatly a¡ecting [14C]AEA uptake (respectively, 42.2 þ 5.3
and 115.5 þ 1.1% of control, see also [13]). We found that,
under these conditions, olvanil still inhibited [14C]AEA accu-
mulation (IC50 = 35 þ 2 WM, n = 3, Fig. 2A, inset) with little
e¡ect on residual [14C]AEA hydrolysis (41.8 þ 2.3% inhibition
at 100 WM), thus showing that the e¡ect of the vanilloid on
AEA uptake is not due to inhibition of AEA hydrolysis.
Three further sets of data are in agreement with this conclu-
sion: (i) olvanil also inhibited [14C]AEA accumulation in J774
macrophages ^ where negligible FAAH activity is expressed
[13,17] ^ with an estimated IC50 = 27 þ 9 WM (n = 3); (ii) ole-
amide, a competitive inhibitor of [14C]AEA hydrolysis and a
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Fig. 2. E¡ect of olvanil and other inhibitors of AEA facilitated
transport on [14C]AEA inactivation by RBL-2H3 cells. A: Dose-de-
pendent inhibition by olvanil of [14C]AEA facilitated di¡usion into
and hydrolysis by intact cells. Data are expressed as radioactivity
associated with AEA in the incubation media or inside cells, or
with ethanolamine produced by AEA hydrolysis, after a 30-min in-
cubation at 37‡C, and are means þ S.D. of three separate experi-
ments carried out in duplicate. No signi¢cant e¡ect of olvanil on
[14C]PEA facilitated di¡usion and hydrolysis in intact cells was ob-
served. The e¡ect of olvanil in the presence of 50 WM p-hydroxy-
mercuribenzoate is shown in the inset. B: Dose-dependent e¡ect of
phloretin, AM404 and oleoylethanolamide on [14C]AEA facilitated
di¡usion into intact cells. Data are expressed as radioactivity associ-
ated with AEA inside cells after a 30-min incubation at 37‡C, and
are means þ S.D. of three separate experiments carried out in dupli-
cate. C: Dose-dependent inhibition by olvanil of [14C]AEA and
[14C]PEA hydrolysis by RBL-2H3 membrane preparations
(10 000Ug pellets). Data are expressed as the radioactivity associ-
ated with ethanolamine produced by AEA or PEA hydrolysis after
a 30-min incubation at 37‡C, and are means of three separate ex-
periments carried out in duplicate. S.D. bars are not shown for the
sake of clarity and were never higher than 5%.
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FAAH substrate [9,14,15,17], did not a¡ect [14C]AEA uptake
by RBL-2H3 cells (data not shown); and (iii) olvanil did not
counteract [14C]PEA di¡usion into RBL-2H3 cells even
though it inhibited [14C]PEA hydrolysis by membrane prepa-
rations as weakly as it did with [14C]AEA hydrolysis
(IC50 = 49 WM, Fig. 2C). We also found that olvanil is stable
to FAAH-catalyzed hydrolysis since, under conditions leading
to e⁄cient [14C]AEA hydrolysis, no oleic acid formation was
observed from incubation of the vanilloid (0.4 mg/ml) with
either RBL-2H3 or N18TG2 cell membranes (data not
shown).
We wanted to assess whether capsaicin and its analogue
pseudocapsaicin also inhibited AEA facilitated transport.
The two compounds were found to reduce the uptake and
the hydrolysis of [14C]AEA by intact RBL-2H3 cells only at
high WM concentrations, capsaicin being the most e¡ective
one on the uptake (estimated IC50 = 46 WM, with IC50s 100
WM for the hydrolysis ; the IC50 values for pseudocapsaicin
were 83 and 60 WM for hydrolysis and uptake, respectively).
The two compounds were not e¡ective against [14C]PEA in-
activation in intact cells (IC50s 100 WM) and only slightly
a¡ected [14C]AEA hydrolysis by membrane preparations
(IC50 = 83 WM and 39 WM, respectively).
We next carried out a series of cannabinoid receptor bind-
ing experiments with olvanil, capsaicin and pseudocapsaicin.
We used membrane preparations from guinea pig forebrain
(GPF) and mouse neuroblastoma N18TG2 cells, which selec-
tively express the CB1 receptor subtype [18,19], as well as
membranes from CHO cells transfected with CB2 receptor
cDNA (CHO-CB2 cells). The high a⁄nity ligand [3H]CP
55 940, which binds to both cannabinoid receptor subtypes,
was used for GPF and CHO-CB2 cell membranes, whereas
the selective CB1 antagonist [3H]SR 141716A was used for
N18TG2 cell membranes [19]. We found that olvanil could
displace both radiolabelled ligands from CB1 receptor-con-
taining membranes, although only at WM concentrations,
but not [3H]CP 55 940 from CHO-CB2 cell membranes (Table
1). Furthermore, olvanil was almost inactive in displacing
[3H]WIN 55 212-2 from RBL-2H3 cell membranes, which
also selectively express CB2 receptors [16]. The Ki values ob-
tained for olvanil for the displacement of [3H]CP 55 940 from
GPF membranes varied between 4.54 and 11.98 WM, with an
average value of 7.08 WM. AEA in the same assay exhibited a
Ki value of 0.48 WM. The Ki for olvanil displacement of
[3H]SR 141716A from N18TG2 cell membranes was signi¢-
cantly lower (1.64 þ 0.36 WM, n = 3) and similar to that found
for AEA (1.91 þ 0.31 WM, n = 3). One reason for these discrep-
ancies may be the use of di¡erent experimental procedures,
membrane preparations and radioligands in these experiments
(see Section 2). Indeed, £uctuations in the Ki values reported
for anandamide (from low-middle to high nM concentrations)
when using di¡erent procedures have been pointed out [7],
and di¡erences of more than 50-fold exist between some of
the reported Ki values of CP 55 940 for the displacement of
[3H]CP 55 940 from CB1 receptors (see Table 2 in [7]). An-
other possibility, i.e. that olvanil is more potent in displacing
[3H]SR 141716A than [3H]CP 55 940 because olvanil and SR
141716A behave as inverse agonists, is ruled out by our data.
In fact, although SR 141716A under certain conditions may
be an inverse agonist ([7,9] and references cited therein), we
found olvanil to behave as a cannabinoid receptor agonist.
We measured the e¡ect on forskolin-induced cAMP forma-
tion ^ an intracellular event whose inhibition is coupled to
CB1 receptor activation [20] ^ in intact N18TG2 cells, which
have been often utilized to study the e¡ect of cannabimimetic
compounds on adenylate cyclase [20]. As shown in Fig. 3,
olvanil behaved as an agonist in this assay, and exhibited an
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Fig. 3. Dose-dependent inhibition by olvanil and anandamide of
forskolin-induced cAMP formation in N18TG2 cells. The e¡ect of
0.5 WM SR 141716A on olvanil inhibitory action is also shown.
Data are expressed as percent of cAMP levels in cells stimulated
with 1 WM forskolin (66.6 þ 14.1 pmols/well), and are means
þ S.E.M. of three separate experiments. cAMP levels in unstimu-
lated cells were 7.7 þ 3.3 pmols/well.
Table 1
Ki values (WM) for olvanil, pseudocapsaicin and anandamide binding to membrane preparations from various sources using di¡erent cannabi-
noid receptor ligands
CB1 CB2
GPF+[3H]CP 55 940 N18TG2+[3H]SR 141716A CHO-CB2+[3H]CP 55 940 RBL-2H3+[3H]WIN 55 212-2
Olvanil 7.08 þ 1.41 1.64 þ 0.36 s 20 s 15
Pseudocapsaicin 6.16 þ 0.13 1.20 þ 0.28 s 20 N.D.
Anandamide 0.48 þ 0.04 1.91 þ 0.31 0.371 þ 0.102 [18] 0.03 [16]
Concentrations in the range 0.1^10 WM were tested. Data are means þ S.E.M. of at least three separate experiments. For olvanil displacement of
[3H]CP 55 940 from CHO-CB2 cell membranes and of [3H]WIN 55 212-2 from RBL-2H3 cell membranes, Ki values higher than 20 and 15 WM can
be predicted from the observation that the compound exhibited, respectively, 0 and 6.7 þ 2.3% displacement at 1 WM and 19.5 þ 1.5% and
32.0 þ 2.1% displacement at 10 WM. The same applies to pseudocapsaicin (15.8 þ 2.8% displacement at 10 WM for CHO-CB2 cell membranes).
The Ki values for anandamide in these two cell membrane preparations, calculated by using a methodology similar to the ones described here, have
been already reported [16,18]. N.D. = not determined.
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IC50 value of 1.60 WM similar to the Ki value for the displace-
ment of [3H]SR 141716A observed in membranes from the
same cells. Olvanil was more potent than AEA (IC50 = 3.20
WM), probably due to its major stability to enzymatic degra-
dation (see above). Furthermore, olvanil inhibition of forsko-
lin-induced cAMP formation was reversed by 0.5 WM SR
141716A, thus proving that this e¡ect was mediated by CB1
receptors. Clearly, further studies are still needed in order to
characterize the CB1-binding properties of olvanil more fully.
These studies may also indicate which of the structural fea-
tures of vanilloids need to be modi¢ed in order to improve
their weak CB1-binding activity. Interestingly, we found that
also pseudocapsaicin displaced cannabinoid ligands from
CB1, but not CB2, receptor-containing membrane prepara-
tions (Ki = 6.16 WM for GPF membranes and 1.20 WM for
N18TG2 cell membranes, Table 1), whereas capsaicin caused
no displacement at 10 WM (data not shown). This ¢nding is in
agreement with the widely accepted concept that a linear,
saturated aliphatic chain of at least ¢ve carbon atoms (Fig.
1) must be present in the molecule to allow the interaction
with CB1 receptors [30].
In summary, we have shown that the long chain analogue
of capsaicin, olvanil, can e⁄ciently interact with at least one
of the four proteins of the ‘endogenous cannabinoid system’
studied here. Olvanil (i) inhibits AEA facilitated transport
into RBL-2H3 cells ; (ii) is a weak agonist at CB1, but not
CB2, receptors; and (iii) very weakly inhibits AEA hydrolysis
by FAAH-containing membrane preparations. Except for a
weak inhibition of AEA uptake, capsaicin does not exhibit
similar properties, whereas pseudocapsaicin is inactive on
the AEA transporter but weakly binds to CB1 receptors.
Both AEA and olvanil were shown previously to exert potent
vasodilatory, analgesic and anti-in£ammatory actions [4^
6,21^24], although probably with di¡erent mechanisms of ac-
tion. While such e¡ects of AEA seem to be mediated by can-
nabinoid receptors located on sensory/sympathetic ¢bers,
smooth muscle, endothelial cells and leukocytes [7,21^23], ol-
vanil actions are probably due to interaction with ^ and sub-
sequent desensitization of ^ selective polymodal sensory noci-
ceptors, the vanilloid receptors [5]. While AEA has been
recently shown to inhibit the release of calcitonin gene-related
peptide (CGRP) from e¡erent sensory neurons and in£amed
tissues [22,23], the opposite e¡ect has been described for olva-
nil [6]. However, given the likely involvement of the ‘endoge-
nous cannabinoid system’ in the control of thermal hyperal-
gesia [22] and the reported activation of VR1 vanilloid
receptors by noxious heat [2], it is possible that common path-
ways underlie the analgesic actions of both compounds, at
least during thermal nociception. On the basis of the data
reported here, and of the spinal mechanism of action pro-
posed for olvanil-induced antinociception [25], it may be hy-
pothesized that part of the analgesic actions observed with
olvanil in vivo [4,5] is due to potentiation of the ‘tonal’
down-regulation of thermal nociception e¡ected by spinal en-
docannabinoids [22,23]. This potentiation may be e¡ected
through inhibition of AEA facilitated transport into periph-
eral ¢bers and/or blood cells and subsequent enhancement of
endogenous AEA levels. Also activation of CB1 receptors
may occur when using the high (s 200 mg/kg body weight)
concentrations of olvanil often reported in the literature [26^
28]. Conversely, since AEA is not capable of inducing a typ-
ical receptor-mediated capsaicin response, i.e. CGRP release
from rat or mouse lumbar spinal cord [23], it is unlikely that
the endocannabinoid interacts with vanilloid receptors. In
conclusion, apart from suggesting the necessity of a general
re-evaluation of the pharmacology and biochemistry of long
chain capsaicin analogues (reviewed in [28]), the data de-
scribed in this paper support a case for interactions between
some synthetic vanilloids and the cannabinoid system and
prompt further studies in this direction. Furthermore, the
¢nding of the weak cannabimimetic actions of olvanil and
pseudocapsaicin may open the way to the design of a novel
class of analgesics with a multiple mechanisms of action.
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